Atara Biotherapeutics Net Worth
Atara Biotherapeutics Net Worth Breakdown | ATRA |
Atara Biotherapeutics Net Worth Analysis
Atara Biotherapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Atara Biotherapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Atara Biotherapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Atara Biotherapeutics' net worth analysis. One common approach is to calculate Atara Biotherapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Atara Biotherapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Atara Biotherapeutics' net worth. This approach calculates the present value of Atara Biotherapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Atara Biotherapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Atara Biotherapeutics' net worth. This involves comparing Atara Biotherapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Atara Biotherapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Atara Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Atara Biotherapeutics' net worth research are outlined below:
| Atara Biotherapeutics had very high historical volatility over the last 90 days | |
| Atara Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 128.94 M. Net Loss for the year was (85.4 M) with profit before overhead, payroll, taxes, and interest of 35.56 M. | |
| Atara Biotherapeutics currently holds about 331.31 M in cash with (68.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.51. | |
| Atara Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Atara Biotherapeutics, Inc. Receives 17.75 Average Target Price from Brokerages |
Atara Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Atara Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Atara Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Atara Biotherapeutics Target Price Consensus
Atara target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Atara Biotherapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Strong Buy |
Most Atara analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Atara stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Atara Biotherapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAtara Biotherapeutics Target Price Projection
Atara Biotherapeutics' current and average target prices are 7.14 and 16.00, respectively. The current price of Atara Biotherapeutics is the price at which Atara Biotherapeutics is currently trading. On the other hand, Atara Biotherapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Atara Biotherapeutics Market Quote on 25th of May 2025
Target Price
Analyst Consensus On Atara Biotherapeutics Target Price
Know Atara Biotherapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Atara Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atara Biotherapeutics backward and forwards among themselves. Atara Biotherapeutics' institutional investor refers to the entity that pools money to purchase Atara Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2025-03-31 | 25.3 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 25 K | Birchview Capital, Lp | 2024-12-31 | 22 K | Gsa Capital Partners Llp | 2025-03-31 | 19.4 K | Renaissance Technologies Corp | 2025-03-31 | 17.4 K | Fmr Inc | 2025-03-31 | 17.2 K | Bridgeway Capital Management, Llc | 2025-03-31 | 14 K | Cubist Systematic Strategies, Llc | 2024-12-31 | 12.7 K | Northern Trust Corp | 2024-12-31 | 11.2 K | Ecor1 Capital, Llc | 2024-12-31 | 532.1 K | Redmile Group, Llc | 2024-12-31 | 441.7 K |
Follow Atara Biotherapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 48.52 M.Market Cap |
|
Project Atara Biotherapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | 3.28 | 3.44 | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | 0.88 | 0.92 |
When accessing Atara Biotherapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Atara Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Atara Biotherapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Atara Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atara Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Atara Biotherapeutics' management manipulating its earnings.
Evaluate Atara Biotherapeutics' management efficiency
Atara Biotherapeutics has return on total asset (ROA) of (0.0177) % which means that it has lost $0.0177 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.1486) %, meaning that it created substantial loss on money invested by shareholders. Atara Biotherapeutics' management efficiency ratios could be used to measure how well Atara Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Atara Biotherapeutics' Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.92, whereas Return On Tangible Assets are forecasted to decline to (0.82). At present, Atara Biotherapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 287 M, whereas Total Assets are forecasted to decline to about 103.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (12.99) | (12.34) | |
| Tangible Book Value Per Share | (12.99) | (12.34) | |
| Enterprise Value Over EBITDA | (1.56) | (1.64) | |
| Price Book Value Ratio | (1.02) | (1.08) | |
| Enterprise Value Multiple | (1.56) | (1.64) | |
| Price Fair Value | (1.02) | (1.08) | |
| Enterprise Value | 99.3 M | 86.6 M |
The strategic initiatives led by Atara Biotherapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 0.3472 | Revenue | Quarterly Revenue Growth 2.588 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atara Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atara Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atara Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Atara Biotherapeutics Corporate Filings
F3 | 23rd of May 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 21st of May 2025 Other Reports | ViewVerify | |
F4 | 20th of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 16th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Atara Biotherapeutics Earnings Estimation Breakdown
The calculation of Atara Biotherapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Atara Biotherapeutics is estimated to be -0.32 with the future projection ranging from a low of -0.32 to a high of -0.32. Please be aware that this consensus of annual earnings estimates for Atara Biotherapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.32 Lowest | Expected EPS | -0.32 Highest |
Atara Biotherapeutics Earnings Projection Consensus
Suppose the current estimates of Atara Biotherapeutics' value are higher than the current market price of the Atara Biotherapeutics stock. In this case, investors may conclude that Atara Biotherapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Atara Biotherapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2025 | Current EPS (TTM) | |
| 5 | 49.46% | 3.5 | -0.32 | -2.26 |
Atara Biotherapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Atara Biotherapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Atara Biotherapeutics predict the company's earnings will be in the future. The higher the earnings per share of Atara Biotherapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Atara Biotherapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Atara Biotherapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Atara Biotherapeutics should always be considered in relation to other companies to make a more educated investment decision.Atara Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Atara Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-06-10 | 2025-03-31 | -1.925 | 3.5 | 5.425 | 281 | ||
2025-03-26 | 2024-12-31 | -3.4875 | -1.19 | 2.2975 | 65 | ||
2024-10-30 | 2024-09-30 | -17.274 | -2.93 | 14.344 | 83 | ||
2024-08-12 | 2024-06-30 | -1.56 | -3.1 | -1.54 | 98 | ||
2024-05-09 | 2024-03-31 | -0.26 | -0.23 | 0.03 | 11 | ||
2024-03-28 | 2023-12-31 | -0.48 | -0.56 | -0.08 | 16 | ||
2023-11-01 | 2023-09-30 | -0.66 | -0.66 | 0.0 | 0 | ||
2023-08-08 | 2023-06-30 | -0.67 | -0.68 | -0.01 | 1 | ||
2023-05-08 | 2023-03-31 | -0.39 | -0.72 | -0.33 | 84 | ||
2023-02-08 | 2022-12-31 | -0.51 | -0.72 | -0.21 | 41 | ||
2022-11-08 | 2022-09-30 | -0.78 | -0.82 | -0.04 | 5 | ||
2022-08-08 | 2022-06-30 | -0.93 | -0.31 | 0.62 | 66 | ||
2022-05-05 | 2022-03-31 | -0.98 | -0.87 | 0.11 | 11 | ||
2022-02-28 | 2021-12-31 | -0.69 | -0.96 | -0.27 | 39 | ||
2021-11-04 | 2021-09-30 | -0.94 | -0.9 | 0.04 | 4 | ||
2021-08-09 | 2021-06-30 | -0.89 | -0.91 | -0.02 | 2 | ||
2021-05-04 | 2021-03-31 | -0.92 | -0.86 | 0.06 | 6 | ||
2021-03-01 | 2020-12-31 | -0.74 | -0.95 | -0.21 | 28 | ||
2020-11-09 | 2020-09-30 | -1.09 | -0.92 | 0.17 | 15 | ||
2020-08-05 | 2020-06-30 | -1.18 | -1.14 | 0.04 | 3 | ||
2020-05-06 | 2020-03-31 | -1.43 | -1.2 | 0.23 | 16 | ||
2020-02-27 | 2019-12-31 | -1.34 | -1.36 | -0.02 | 1 | ||
2019-11-07 | 2019-09-30 | -1.44 | -1.31 | 0.13 | 9 | ||
2019-08-08 | 2019-06-30 | -1.5 | -1.6 | -0.1 | 6 | ||
2019-05-09 | 2019-03-31 | -1.51 | -1.44 | 0.07 | 4 | ||
2019-02-26 | 2018-12-31 | -1.31 | -1.75 | -0.44 | 33 | ||
2018-11-06 | 2018-09-30 | -1.13 | -1.29 | -0.16 | 14 | ||
2018-08-01 | 2018-06-30 | -0.98 | -1.15 | -0.17 | 17 | ||
2018-05-08 | 2018-03-31 | -0.92 | -1.05 | -0.13 | 14 | ||
2018-02-27 | 2017-12-31 | -1.14 | -1.15 | -0.01 | 0 | ||
2017-11-09 | 2017-09-30 | -0.98 | -1.02 | -0.04 | 4 | ||
2017-08-07 | 2017-06-30 | -0.89 | -0.94 | -0.05 | 5 | ||
2017-05-04 | 2017-03-31 | -0.74 | -0.88 | -0.14 | 18 | ||
2017-03-09 | 2016-12-31 | -0.98 | -0.63 | 0.35 | 35 | ||
2016-11-04 | 2016-09-30 | -0.77 | -0.88 | -0.11 | 14 | ||
2016-08-08 | 2016-06-30 | -0.61 | -0.66 | -0.05 | 8 | ||
2016-05-05 | 2016-03-31 | -0.55 | -0.58 | -0.03 | 5 | ||
2016-03-03 | 2015-12-31 | -0.48 | -0.75 | -0.27 | 56 | ||
2015-11-05 | 2015-09-30 | -0.56 | -0.43 | 0.13 | 23 | ||
2015-08-06 | 2015-06-30 | -0.44 | -0.43 | 0.01 | 2 | ||
2015-05-07 | 2015-03-31 | -0.44 | -0.42 | 0.02 | 4 | ||
2015-02-26 | 2014-12-31 | -0.35 | -0.67 | -0.32 | 91 |
Atara Biotherapeutics Corporate Management
| Rajani MD | Senior Officer | Profile | |
| Eric Hyllengren | Executive Officer | Profile | |
| Jakob MD | Ex RD | Profile | |
| Kerry Daly | Head Communications | Profile | |
| Jill Henrich | Executive Quality | Profile | |
| Utpal MBA | Ex CFO | Profile | |
| Alex Chapman | Vice Relations | Profile |
Already Invested in Atara Biotherapeutics?
The danger of trading Atara Biotherapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Atara Biotherapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Atara Biotherapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Atara Biotherapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.26) | Revenue Per Share | Quarterly Revenue Growth 2.588 | Return On Assets | Return On Equity |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.